Predictive Oncology Inc., will collaborate with CvergenX, Inc., on the first-ever genomics-based artificial intelligence approach to personalized radiotherapy and drug discovery. The objective of this collaboration is to leverage and maximize the combined power of their respective proprietary technologies and domain expertise for a common purpose. By applying Predictive Oncology’s drug discovery, artificial intelligence and machine learning capabilities (PEDAL), and the Cvergenx precision ...